Matthew Fraley, MD
Cardiovascular Disease · Florissant, MONPI 1326187352
Payments from drug & device makers
Across 647 payments — averaging $282.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$161K
- Amarin Pharma, Inc.$15K
- Novartis$1K
- Amgen$813
- Sanofi-aventis U.S. LLC$442
- Pfizer$412
- plus $4K from 32 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$166,72991%
- Travel & lodging$4,6793%
- Food & beverage$10,8946%
- Education$440%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 234 | $160,788 |
| Amarin Pharma, Inc. | 44 | $15,214 |
| Novartis | 87 | $1,407 |
| Amgen | 44 | $813 |
| Sanofi-aventis U.S. LLC | 25 | $442 |
| Pfizer | 25 | $412 |
| E.r. Squibb & Sons, L.L.C. | 21 | $370 |
| Boehringer Ingelheim | 18 | $358 |
| Regeneron Healthcare Solutions, Inc. | 15 | $337 |
| Merck | 16 | $322 |
| AstraZeneca | 21 | $310 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 19 | $279 |
| Boston Scientific | 9 | $255 |
| Scpharmaceuticals Inc. | 7 | $173 |
| Esperion Therapeutics, Inc. | 8 | $124 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $110 |
| Bayer | 7 | $110 |
| Novo Nordisk | 5 | $101 |
| Medtronic | 2 | $88 |
| Cvrx, Inc. | 6 | $85 |
| Daiichi Sankyo Inc. | 3 | $58 |
| Lexicon Pharmaceuticals, Inc. | 3 | $56 |
| Alnylam Pharmaceuticals Inc. | 2 | $49 |
| Edwards Lifesciences | 3 | $45 |
| Astellas Pharma US Inc | 2 | $44 |
| Abbott | 2 | $37 |
| Irhythm Technologies, Inc. | 2 | $35 |
| Heartflow, Inc. | 1 | $31 |
| Abiomed | 1 | $31 |
| Gilead | 2 | $27 |
| Arbor Pharmaceuticals, Inc. | 2 | $24 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $21 |
| Lundbeck LLC | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $15 |
| AbbVie | 1 | $14 |
| Amryt Pharma Holdings Ltd | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$182,646 in reported general payments places this provider in the 90th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 543 | $579,800 |
| EliquisApixaban | 500 | $449,568 |
| EntrestoSacubitril/Valsartan | 281 | $257,949 |
| ArcalystRilonacept | 11 | $253,604 |
| Repatha SureclickEvolocumab | 234 | $169,017 |
| BrilintaTicagrelor | 86 | $62,364 |
| JardianceEmpagliflozin | 56 | $62,333 |
| Repatha PushtronexEvolocumab | 45 | $39,201 |
| MultaqDronedarone Hcl | 22 | $37,257 |
| Praluent PenAlirocumab | 43 | $29,250 |
| VascepaIcosapent Ethyl | 43 | $28,916 |
| Icosapent Ethyl | 38 | $10,307 |
| NexletolBempedoic Acid | 19 | $7,676 |
| Atorvastatin Calcium | 653 | $6,573 |
| Metoprolol Succinate | 507 | $5,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $160,788 | $579,800543 claims |
| PfizerEliquis | $412 | $449,568500 claims |
| NovartisEntresto | $1,407 | $257,949281 claims |
| Kiniksa Pharmaceuticals International, PLCArcalyst | $110 | $253,60411 claims |
| AstraZenecaBrilinta | $310 | $62,36486 claims |
| Boehringer IngelheimJardiance | $358 | $62,33356 claims |
| Sanofi-aventis U.S. LLCMultaq | $442 | $37,25722 claims |
| Esperion Therapeutics, Inc.Nexletol | $124 | $7,67619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 391 cardiovascular disease providers in Missouri.
Other cardiovascular disease in Florissant
- Mikhail KosiborodKansas City$27.8M
- Mohammad TahirSaint Louis$2.7M
- John SpertusKansas City$2.3M
- Joshua MitchellSaint Louis$1.4M
- Nathan StitzielSaint Louis$1.2M
- Daniel KellySaint Louis$1.1M
- Georges ChahoudSaint Louis$967K
- Jiafu OuSaint Louis$853K
- William BowenSaint Louis$726K
- Omar AlmousalliFestus$690K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.